Update on stem cell transplantation for systemic sclerosis: Recent trial results

Current Rheumatology Reports

Volumn 15, Issue 5, 2013, Pages

  Naraghi, Kamran ^a   Van Laar, Jacob M ^a,b  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anti thymocyte globulin; ASSIST trial; ASTIS trial; Clinical trials; Cyclophosphamide; G CSF; Hematopoietic stem cell transplantation; Immune ablation; SCOT trial; Systemic sclerosis; Therapies

Indexed keywords

ABATACEPT; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THYMOCYTE ANTIBODY; TOCILIZUMAB;

ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CD34 SELECTION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FORCED VITAL CAPACITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; LEUKAPHERESIS; LONG TERM SURVIVAL; LUNG FIBROSIS; MODIFIED RODNAN SKIN SCORE; MORTALITY; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERODERMA; SCORING SYSTEM; SECOND CANCER; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; WHOLE BODY RADIATION; AUTOTRANSPLANTATION; DIFFUSE SCLERODERMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; REVIEW; SURVIVAL RATE; PROCEDURES; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84875009952     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0326-2     Document Type: Article

References (38)

1. Varga J, Abraham D. Systemic sclerosis: a prototype multisystem fibrotic disorder. J Clin Invest. 2007;117:557-67. (Pubitemid 46348510)
2. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine. 2002;81:139-53. (Pubitemid 34218569)
3. Tyndall AJ, Bannert B. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809-15.
4. Nihtyanova SI, Tang SI, Coghlan JG, Wells AU, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM. 2010;103:109-15.
5. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
6. Elhai M, Meunier M, Matucci-Cerinic M, et al. on behalf of EUSTAR (EULAR Scleroderma Trials and Research group): Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2012. [Epub ahead of print].
7. EU Clinical Trials Register: A phase II/III, multicenter, randomized, double blind, placebo-controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis. Available at https://www.clinicaltrialsregister.eu/ctrsearch/search?query= systemic+sclerosis+and+tocilizumab. Accessed January 2013.
8. van Laar JM. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther. 2010;12:112-6.
9. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol. 2011;38:289-96.
10. Marmont A, Tyndall A, Gratwohl A, Vischer T. Hematopoietic precursor-cell transplants for autoimmune-diseases. Lancet. 1995;345:978.
11. van Laar JM, Tyndall A. Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control. 2003;10:57-65. (Pubitemid 36231963)
12. Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. Curr Opin Rheumatol. 2011;23:519-29.
13. Hügle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther. 2008;10:217.
14. The European Group for Blood and Marrow transplantation: EBMT activity survey 2010. Available at http://www.ebmt.org/Contents/Research/ TransplantActivitySurvey/Results/Documents/Survey-2010-website-set-Final- Nov2011%20(1).pdf. Accessed January 2013.
15. Hügle T, van Laar JM. Allogeneic stem cell transplantation for rheumatic autoimmune diseases. F1000 Med Rep. 2010;2:22.
16. Cipriani P, Carubbi F, Liakouli V, et al. Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy. Autoimmun Rev. 2012. doi: 10.1016/j.autrev.2012.10.004 [Epub ahead of print].
17. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol. 2005;141:1-9. (Pubitemid 40904634)
18. Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008;3:e1452. (Pubitemid 351248269)
19. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic stem cell transplantation in severe autoimmune diseases: updated guidelines of the European Group for Blood and Bone Marrow Transplantation. Bone Marrow Transpl. 2012;47:770-90.
20. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60:577-84. (Pubitemid 32493984)
21. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 2002;100:1602-10. (Pubitemid 34925135)
22. Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol. 2002;119:726-39. (Pubitemid 35366216)
23. Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004;63:974-81. (Pubitemid 38961924)
24. Vonk MC, Marjanovic Z, van den Hoogen FH, et al. Longterm follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008;67:98-104.
25. • Henes JC, Schmalzing M, Vogel W, et al. Optimization of autologous stem cell transplantation for systemic sclerosis - a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol. 2012;39:269-75. Single center, long-term follow-up study in 26 transplanted SSc patients.
26. Burt RK, Oliveira MC, Shah SJ, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet. 2013. doi: 10.1016/S01406736(12)62114-X. [Epub ahead of print]. Retrospective analysis of 2 cohorts of SSc patients treated with the same transplant regimen making the case for fluid challenge during right heart catheterization as a means to optimize patient selection.
27. • Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498-506. Small, randomized, controlled trial showing superior efficacy on skin thickening and lung function of HSCT when compared to a short course of intravenous pulse cyclophosphamide.
28. ClinicalTrials.gov: Autologous stem cell systemic sclerosis immune suppression trial (DISclRituxan). Available at http://www.clinicaltrials.gov/ ct2/show/record/NCT01445821?term=ASSIST+Trial+systemic+sclerosis&rank=1. Accessed January 2013.
29. van Laar JM, Farge D, Tyndall A. Stem cell transplantation: a treatment option for severe systemic sclerosis? Ann Rheum Dis. 2008;67 Suppl 3:iii35-8.
30. van Laar JM, Farge D, Sont JK, et al. The ASTIS trial: autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. EULAR, Annual Congress of the European League Against Rheumatism. Ann Rheum Dis. 2012;71 suppl 3:151.
31. Farge D, van Laar JM, Sont JK, et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse therapy cyclophosphamide for severe or rapidly progressive systemic sclerosis, the ASTIS Trial. Blood (ASH Ann Meet Abstr). 2012;120:964.
32. ClinicalTrials.gov: Scleroderma: Cyclophosphamide or Transplantation (SCOT). Available at http://www.clinicaltrials.gov/ct2/show/NCT00114530?term= SCOT+trial&rank=6. Accessed January 2013.
33. • Craciunescu OI, Steffey BA, Kelsey CR, et al. Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial. Int J Radiat Oncol Biol Phys. 2011;79:1248-55. Detailed study discussing the rationale and practicalities of renal shielding and dosimetry related to total body irradiation as used in the SCOT trial.
34. Daikeler T, Tichelli A, Passweg J. Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res. 2012;71:439-44.
35. • Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011;118:1693-8. Comprehensive retrospective analysis of secondary autoimmune diseases in patients transplanted for primary autoimmune diseases including systemic sclerosis.
36. Chang G, Orav EJ, McNamara T, et al. Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome. Cancer. 2004;101:782-9. (Pubitemid 39030935)
37. Montori VM, Devereaux PJ, Adhikari NKJ, et al. Randomized trials stopped early for benefit. A systematic review. JAMA. 2005;294:2203-9. (Pubitemid 41571138)
38. Tyndall A. Stem cells: HSCT for systemic sclerosis-swallows and summers. Nat Rev Rheumatol. 2011;7:624-6.